Product image of Ibosat (Ibandronic Acid) supplied by GNH India

Ibosat

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibosat (Ibandronic Acid)

Ibandronic Acid, the active ingredient in Ibosat, is a bisphosphonate presented as a tablet for oral use. It works by inhibiting osteoclast‑mediated bone resorption and is indicated for the treatment of osteoporosis and Paget's disease of bone in adults who are at increased risk of fractures.

GNH India supplies Ibosat as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide in accordance with EU quality standards and regulatory requirements through reliable logistics support.

Manufacturer / TM Owner

Libytec Pharmaceutical S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibosat is a bisphosphonate that acts on bone remodeling processes to improve skeletal strength.

  • Osteoporosis: reduces risk of vertebral, hip and other fractures by increasing bone mineral density.
  • Paget's disease of bone: normalizes abnormal bone turnover and alleviates bone pain.
  • Glucocorticoid‑induced osteoporosis: helps maintain bone density in patients receiving long‑term corticosteroid therapy.

How It Works

  • Ibandronic Acid binds avidly to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the drug‑coated bone surface, the compound is internalized and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting prenylation of small G‑proteins essential for osteoclast function, leading to reduced bone resorption. Thereby, the drug contributes to increased bone mineral density over time and improved skeletal strength.

Side Effects

Ibosat may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia, or constipation.
  • Musculoskeletal pain: transient bone, joint or muscle aches.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: exposed bone in the maxillofacial region.
  • Atypical femur fracture: low‑energy fracture of the subtrochanteric region.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before prescribing Ibosat, clinicians should consider several safety measures.

  • Assess renal function: evaluate creatinine clearance before initiating therapy.
  • Ensure adequate calcium and vitamin D: correct deficiencies prior to treatment.
  • Review esophageal health: avoid administration in patients with active esophageal disorders.
  • Monitor for hypocalcemia: check serum calcium levels and treat low calcium before dosing.
  • Avoid concomitant use with other bisphosphonates: do not combine with similar agents.
  • Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Avoid Interactions

Ibosat can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Antacids or calcium supplements within 2 hours: they reduce oral absorption of ibandronate.
  • Concomitant use of other bisphosphonates: additive risk of oversuppression of bone turnover.
  • Nephrotoxic drugs (e.g., aminoglycosides): increase risk of renal impairment.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may enhance bone loss, requiring close monitoring of bone density.
  • Warfarin: ibandronate can potentiate anticoagulant effect, so INR should be monitored.

Frequently Asked Questions

Ibosat contains Ibandronic Acid, a bisphosphonate indicated for the treatment of osteoporosis and Paget's disease of bone in adult patients. It helps reduce the risk of fractures by decreasing bone resorption and improving overall bone strength.

Ibandronic Acid binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and blocks farnesyl pyrophosphate synthase in the mevalonate pathway, impairing osteoclast function and thereby reducing bone breakdown.

The specific dose and dosing schedule of Ibosat are determined by the prescribing healthcare professional based on the patient’s condition, renal function, and other clinical factors. Patients should follow the prescriber’s instructions exactly.

Safety data for Ibandronic Acid in pregnancy and lactation are limited. It is generally recommended to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk, and this decision should be made by a qualified clinician.

To order Ibosat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibosat (ibandronate) is a potent, once‑monthly oral bisphosphonate, offering similar efficacy to weekly alendronate or yearly zoledronic acid for osteoporosis. Its dosing convenience and specific safety profile, such as a lower incidence of gastrointestinal irritation, may make it preferable for some patients.

Ibosat tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture. Keep the product out of reach of children and avoid exposure to direct sunlight or excessive heat.

Ibosat is taken orally, usually with a full glass of plain water on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during that time to maximize absorption.

The most serious adverse events linked to ibandronate include osteonecrosis of the jaw, atypical femur fractures, severe hypersensitivity reactions, and acute renal impairment. Patients should be monitored for these conditions, especially if they have pre‑existing risk factors.

Ibosat is contraindicated in patients with known hypersensitivity to ibandronic acid or other bisphosphonates, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with active esophageal disorders that could be aggravated by oral tablets.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT